Clinical trial · Interventional
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
NCT00186277CI-TRIAL-00004634completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
| Taxotere | Drug | Docetaxel | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Tolerability of the this combination in patients with recurrent metastatic bladder cancer.
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
* Patient Population Type: Advanced Muscle Invasive Bladder Cancer * Prior Therapy: One prior therapy for advanced disease * Disease: Measurable disease * ECOG Performance: 0,1 * Indication: Histologically Proven Carcinoma of the bladder * For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception * Allergies: No known allergy to one of the study drugs * Patient Status: * No CNS metastases * No peripheral neuropathy \> grade1 * No other serious concomitant illness * Fully recovered from any prior therapy * Informed Consent: Patient and doctor have signed informed consent * Lower Age Limit: Lower age limit \>18 * Upper Age Limit: Upper Age Limit \<70 * ANC: ANC \>1500/mm3 or WBC \> 3000/mm3 * Platelets: Platelets \>100,000/mm3 * Creatinine: Creatinine \<1.8mg/dL * Bilirubin: Bilirubin \<=2.0 x ULN * SGPT: SGPT (ALT) \<=1.5 x ULN (\<4xULN if liver metastases present) * RBC: Hemoglobin \> 9.0g/dL * Cardiovascular: No active congestive heart failure, no uncontrolled angina, no myocardial infarction within the past 6 months * Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma) * No prior exposure to Oxaliplatin * No cytotoxics or radiation 4 weeks prior to enrolling on protocol * PT/PTT normal
References
Publications (0)
Data not yet available
No reference posted for this study.